{"name":"Lyvgen Biopharma Holdings Limited","slug":"lyvgen-biopharma-holdings-limited","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"LVGN6051","genericName":"LVGN6051","slug":"lvgn6051","indication":"Other","status":"phase_1"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"LVGN6051 Monoclonal Antibody Injection","genericName":"LVGN6051 Monoclonal Antibody Injection","slug":"lvgn6051-monoclonal-antibody-injection","indication":"Metastatic non-small cell lung cancer, PD-L1 positive","status":"phase_2"}]}],"pipeline":[{"name":"LVGN6051","genericName":"LVGN6051","slug":"lvgn6051","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"LVGN6051 Monoclonal Antibody Injection","genericName":"LVGN6051 Monoclonal Antibody Injection","slug":"lvgn6051-monoclonal-antibody-injection","phase":"phase_2","mechanism":"LVGN6051 targets the PD-1 receptor to inhibit cancer cell growth and immune evasion.","indications":["Metastatic non-small cell lung cancer, PD-L1 positive"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE4xMHVKU1RITHdrZjVaUW1md05BUnU3UzhLMG82YXJHUWtDYnpMTDFEU051UjVWVlFDLTcyb3dpQTZQcTVnempQbmM0ekhjeVBPVlp2NDJyMHl1QllIR3ZF?oc=5","date":"2026-01-13","type":"trial","source":"Nature","summary":"Therapeutic responses in patients with advanced NSCLC enrolled in early-phase clinical trials at MD Anderson - Nature","headline":"Therapeutic responses in patients with advanced NSCLC enrolled in early-phase clinical trials at MD Anderson","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2024-06-25","type":"deal","source":"businesswire.com","summary":"Monoclonal Antibody Collaboration and Licensing Deals Trends Report 2024 with Directory of 974 Partnering Deals Signed by the World's Leading Life Science Companies Since 2016 - ResearchAndMarkets.com","headline":"Monoclonal Antibody Collaboration and Licensing Deals Trends Report 2024 with Directory of 974 Partnering Deals Signed b","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwJBVV95cUxNd0xfQ0dxa0VhdGNvZ1pjd21Td2ZuSS0zbjNqMWtDU1dmNU5CLV8xUkFsdVR5TjJFQTBrdVdudjg0WGN4QUJrdmNJYnZ2TEVTVnFFTXFxQU5STWdKc21XbkNMM0JuWXpqUTNFVklKcUpzTk4yV21DS2lPR1Yxd0dERWUtc1ExOTRfcF84MWI0MFNiLS1ZclZKM0FBS3dUbndRWU4wLUhHM2xndFRFcHVKak52cVUxWS1MM0NlUUQ5NkF2UEJKY1ZtMTRZbkkxenFYVGstVUw3TnNvUHlaQkNpMlAxeXZwdl8wdkFvQVBmbEV2ZXk5YlYzSkV6dkJ2bm9rb2lGWmVJcEw2czgyZEJscFB2cUdrdlRXcllUbnZVVVNxSUx0M0x6YlA0Z0ZNZ29VTVpXbE9Tdw?oc=5","date":"2024-01-08","type":"trial","source":"GlobeNewswire","summary":"HDAC Inhibitor Clinical Trial Pipeline Appears Robust With - GlobeNewswire","headline":"HDAC Inhibitor Clinical Trial Pipeline Appears Robust With","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_1":1,"phase_2":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}